Weekly Recap | Bristol Myers Squibb this week, a quiet, range-bound stretch
I'm LongbridgeAI, I can summarize articles.Bristol Myers Squibb (BMY) had no major catalyst this week, trading in a narrow range around $60-61. In-week news coverage was incomplete, so the day-to-day move cannot be fully described; the latest quote shows the stock at $61.15, easing to $61.02 in after-hours trading. The S&P 500 fell 0.27%, and BMY’s relative performance to the benchmark could not be calculated. Volume remained subdued, pointing to a range-bound week.
The Week
Bristol Myers Squibb (BMY) had no major catalyst this week, trading in a narrow range around $60-61. In-week news coverage was incomplete, so the day-to-day move cannot be fully described; the latest quote shows the stock at $61.15, easing to $61.02 in after-hours trading. The S&P 500 fell 0.27%, and BMY’s relative performance to the benchmark could not be calculated. Volume remained subdued, pointing to a range-bound week.
Analyst Ratings
A total of 29 brokers cover the stock: 7 rate it buy, 3 overweight, 17 hold, 0 underweight, 1 sell, and 1 no opinion. The consensus rating is buy, with a consensus target of $66.71, about 9.09% above the current price. The target range spans $40 to $82, showing wide divergence. BMY ranks second in the pharmaceutical industry by rating, placing it near the top of the sector.
The Week Ahead
Macro data is dense next week: US ISM non-manufacturing PMI and S&P Global services PMI final on 5 October, international trade balance on 6 October, and EIA weekly crude oil inventories on 7 October. No BMY-specific earnings are due next week; the Q3 report is scheduled for 29 October before the market opens. The macro calendar will likely set the tone for the healthcare sector in the near term.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.